The content on this site is intended for healthcare professionals only
Dr Marcia Brose presents data on a randomised phase III study, DECISION, during a press conference at the 2013 ASCO Annual Meeting.
The study found that the targeted drug sorafenib stalls disease progression by five months in patients with metastatic differentiated thyroid cancer that has progressed despite standard radioactive iodine (RAI) therapy. If approved by the FDA, sorafenib would become the first new active drug for this form of thyroid cancer in 40 years.
Transforming cancer care in India: The Access Cancer Care Initiative
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
Advancements in head and neck cancer treatment in India
Advancements in paediatric Acute lymphoblastic leukemia management
Enhancing head and neck oncology: Key insights from the conference
Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
GIST tumours and soft tissue sarcomas
